Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
View / Open Files
Authors
Shu, Shaokun
Lin, Charles Y
Witwicki, Robert M
Tabassum, Doris P
Roberts, Justin M
Janiszewska, Michalina
Huh, Sung Jin
Liang, Yi
Ryan, Jeremy
Doherty, Ernest
Mohammed, Hisham
Guo, Hao
Ekram, Muhammad B
Brown, Jonathan
D'Santos, Clive
Krop, Ian E
Dillon, Deborah
McKeown, Michael
Ott, Christopher
Qi, Jun
Ni, Min
Rao, Prakash K
Duarte, Melissa
Wu, Shwu-Yuan
Chiang, Cheng-Ming
Anders, Lars
Young, Richard A
Letai, Antony
Barry, William T
Long, Henry
Brown, Myles
Liu, X Shirley
Meyer, Clifford A
Bradner, James E
Polyak, Kornelia
Publication Date
2016-01-06Journal Title
Nature
ISSN
0028-0836
Volume
529
Issue
7586
Pages
413-417
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., et al. (2016). Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.. Nature, 529 (7586), 413-417. https://doi.org/10.1038/nature16508
Keywords
Cell Line, Tumor, Chromatin, Animals, Humans, Mice, Azepines, Triazoles, Casein Kinase II, Phosphoserine, Cell Cycle Proteins, Nuclear Proteins, Transcription Factors, Xenograft Model Antitumor Assays, Proteomics, Cell Proliferation, Transcription, Genetic, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Binding, Competitive, Protein Structure, Tertiary, Protein Binding, Phosphorylation, Drug Resistance, Neoplasm, Genome, Human, Female, Protein Phosphatase 2, Mediator Complex Subunit 1, Triple Negative Breast Neoplasms
Sponsorship
Cancer Research UK (C14303_do not transfer)
Identifiers
External DOI: https://doi.org/10.1038/nature16508
This record's URL: https://www.repository.cam.ac.uk/handle/1810/292234
Rights
All rights reserved